AMDHD1 and hematopoietic and lymphoid cell neoplasm: Reportedly, inhibition of the components of the histidine degradation pathway such as HAL and AMDHD1 (amidohydrolase domain containing 1) induces the levels of tetrahydrofolate, which decreases the sensitivity of hematopoietic cancer cells to methotrexate8.